World Health Organization Sounds Alert Over Severe Shortage of Obesity Injections
Fewer than one in 10 people that would benefit from obesity jabs including Wegovy have access to them, warns the WHO as it publishes its inaugural guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a chronic disease that can be addressed with holistic and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant obstacles to widespread access to the jabs that can help people shift considerable body mass, explains the organization.
Weight-Loss Drug Shortage
Even under the present most optimistic case, the production of GLP-1 therapies would only suffice for about 100 million people – less than 10% of the global need, as stated by the WHO.
The guideline calls on governments and firms to increase availability, via approaches like patent sharing.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is due to expire in multiple countries in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so individuals consume fewer calories.
Patients typically begin shedding pounds within a few weeks of starting on the weekly injections.
Research indicates people may see weight return within a year of discontinuing the treatment, when their typical food cravings resume.
To be carrying excess weight elevates your likelihood for contracting medical conditions, like diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
